|
Jul 2
|
Merck's HPV Vaccine Gardasil Remains Key Driver Ahead of Q2 Results, UBS Says
|
|
Jul 2
|
Merck (NYSE:MRK) Gains FDA Priority Review For WINREVAIR PAH Treatment sBLA
|
|
Jul 2
|
What's Fueling Tempus AI's Explosive Sales Growth?
|
|
Jul 2
|
Merck concludes SpringWorks acquisition for $3.4bn
|
|
Jul 2
|
FDA Grants Priority Review for WINREVAIR™ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial
|
|
Jul 2
|
Can China sustain a surge in oncology drug innovation?
|
|
Jul 2
|
Summit Therapeutics (SMMT) Rated Buy on Ivonescimab’s Cancer-Fighting Potential
|
|
Jul 1
|
Trading Rotation Kicks Off 2nd Half of 2025
|
|
Jul 1
|
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
|
|
Jul 1
|
Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth
|
|
Jul 1
|
Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29
|
|
Jun 30
|
BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?
|
|
Jun 30
|
Gilead extends gains after Supreme Court upheld an Obamacare provision
|
|
Jun 28
|
Merck’s (MRK) WINREVAIR Shows Strong Results in HYPERION Trial
|
|
Jun 28
|
Should You Count on MRK for Steady Passive Income?
|
|
Jun 27
|
Cancer Vaccine (Preventative, Therapeutic) Market Research 2025 with Analyst Recommendations-Leveraging AI and Bioinformatics for Precision Development / Pursue Fast-Track and Orphan Drug Designations
|
|
Jun 27
|
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
|
|
Jun 26
|
Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know
|
|
Jun 26
|
Merck’s RSV shot for infants gets key approval despite RFK Jr.’s panel shakeup
|
|
Jun 26
|
ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season
|